Europe Approves Bristol Myers' BCMA-Targeted Multiple Myeloma Immunotherapy

The European Commission (EC) has granted conditional marketing approval for Bristol Myers Squibb & Co's BMY Abecma (idecabtagene vicleucel, ide-cel) for relapsed and refractory multiple myeloma.
Abecma is a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.
The approval comes for patients who have received at least three prior therapies and have demonstrated disease progression on the last treatment.
Related content: Benzinga's Full FDA Calendar.
Price Action: BMY shares are up 1.19% at $68.74 during the market session on the last check Thursday.